|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8871241||EYEPOINT PHARMS||Injectable sustained release delivery devices|| |
(3 years from now)
|US7998108||EYEPOINT PHARMS||Injector apparatus and method of use|| |
(4 years from now)
Yutiq is owned by Eyepoint Pharms.
Yutiq contains Fluocinolone Acetonide.
Yutiq has a total of 2 drug patents out of which 0 drug patents have expired.
Yutiq was authorised for market use on 12 October, 2018.
Yutiq is available in implant;intravitreal dosage forms.
Yutiq can be used as a method of injecting an implant.
The generics of Yutiq are possible to be released after 12 January, 2028.
Market Authorisation Date: 12 October, 2018
Treatment: A method of injecting an implant
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic